Key Benefits:
President of the Republic,
On the report of the Prime Minister and the Minister for Foreign and European Affairs,
Considering articles 52 to 55 of the Constitution;
Vu le Decree No. 53-192 of 14 March 1953 amended on the ratification and publication of international commitments undertaken by France;
Vu le Decree No. 2007-503 of 2 April 2007 publishing the international convention against doping in sport (two annexes), adopted in Paris on 19 October 2005;
Vu le Decree No. 2008-35 of 10 January 2008 publishing the amendment to the annex to the Convention against Doping, adopted on 12 November 2007 in Madrid;
Vu le Decree No. 2009-93 of 26 January 2009 having published the amendment to the annex to the convention against doping, adopted on 13 November 2008 in Strasbourg, and Appendix 1 of the international convention against doping in sport, adopted on 17 November 2008 in Paris,
Decrete:
The amendment to the appendix to the convention against doping, adopted on 18 November 2009 in Strasbourg, and to Annex 1 of the international convention against doping in sport, adopted in Paris on 28 October 2009, will be published in the Official Journal of the French Republic.
The Prime Minister and the Minister for Foreign and European Affairs are responsible for the execution of this decree, which will be published in the Official Journal of the French Republic.
AMENDMENT TO THE ANNEX OF THE CONVENTION AGAINST DOPAGE, ADOPTED 18 NOVEMBER 2009 IN STRASBOURG, AND NEXT 1 OF THE INTERNATIONAL CONVENTION AGAINST SPORT
LIST OF PROHIBITIONS 2010
STANDARD INTERNATIONAL
Effective January 1, 2010.
All prohibited substances must be considered as "specified substances", except substances in classes S1, S2.1 to S2.5, S4.4 and S6.a, and prohibited methods M1, M2 and M3.
SUBSTANCES AND INTERNATIONAL METHODS
EN PERMANENCE (EN ET HORS COMPÉTITION)
SUBSTANCES INTERDITES
S1. Anabolic agents:
Anabolic agents are forbidden.
1. Androgenic anabolic steroids (SAA):
(a) Exogenous SAA (*), including:
1-androstènediol (5-androst-1-ène-3,17-diol) ; 1-androstènedione (5-androst-1-ène-3,17-dione) ; bolandiol (19-norandrostènediol) ; bolaster ; boldénone ; boldione (androsta-1,4-diène-3,17-dione) ; calustérone ; clostébol ; danazol (17-ethynyl-17-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17hydroxy-17-methylandrosta-1,4-diène-3-one); deoxymethyltestosterone (17-methyl-5-androst-2-en-17-ol); drostanolone; ethylestrenol (19-nor-17-pregn-4-en-17-ol) ; fluoxymesterrone ; formationbolone ; ferazabol (17-hydroxy-17-methyl-5-androstano[2,3-c]-furazan) ; gestrinone ; 4-hydroxytestosterone (4,17-dihydroxyandrost-4-en-3-one) ; mestanolone ; mesterolone ; méténolone ; methanediénone (17-hydroxy-17-methylandrosta-1,4-diène-3-one); methandriol; methasterone (2, 17-dimethyl-5-androstane-3-one-17-ol); methyldiénolon (17-hydroxy-17-methylestra-4,9-diène-3-one) ; methyl-1-testosterone (17-hydroxy-17-methyl-5-androst-1-en-3-one) methylnortestosterone (17-hydroxy-17-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltriènolone, 17-hydroxy-17-methylestra-4,9,11-triène-3-one); mibolone; nandrolone; 19-norandrostendione (estr-4-ene-3,17-dione); norboletone; norclostebol; Norethandrolone ; oxabolone ; oxandrolone ; oximesterrone; oxymetholone; prostanozol (17-hydroxy-5-androstano[3,2-c]pyrazole) ; quinbolone ; stanozolol ; stenbolone ; 1-testosterone (17-hydroxy-5-androst-1-ène-3-one) ; tetrahydrogestrinone (18a-homo-pregna-4,9,11-trine-17-ol-3-one); trenbolone and other substances having a similar chemical structure or a biological effect(s) similar(s).
(b) Endogenous SAA (**) by exogenous administration:
Androstènediol (androst-5-ène-3, 17-diol) ; androstènedione (androst-4-ène-3,17-dione) ; dihydrotestosterone (17-hydroxy-5-androstan-3-one) ; prasterone (dehydroepandrosterone, DHEA) ; testosterone and the following metabolites or isomers:
5-androstane-3,17-diol; 5-androstane-3,17-diol; 5-androstane-3,17-diol; 5-androstane-3,17-diol; androst-4-ene-3,17-diol; androst-4-ene-3,17-diol; androst-4-ene-3,17-diol; androst-5-ene-3,17-diol; androst-5-ene-3,17-diol; androst-5-ene-3,17-diol;
4-androstènediol (androst-4-ène-3, 17-diol) ; 5-androstènedione (androst-5-ène-3,17-dione) ; epidihydrotestosterone ; epitestosterone ; 3-hydroxy-5-androstan-17-one; 3-hydroxy-5-androstan-17-one; 19-norandrosterone; 19-norétiocholanolone.
2. Other anabolic agents, including but not limited to:
Clenbuterol, selective modulators of androgenic receptors (SARMs), tibolone, zéranol, zilpatrol.
For the purposes of this document:
(*) "exogenous" means a substance that cannot usually be produced naturally by the human body.
(**) "endogenous" means a substance that can be produced naturally by the human body.
S2. Peptide hormones, growth factors and related substances:
The following substances and their release factors are prohibited:
1. Erythropoiesis stimulants [e.g. erythropoietin (EPO), darbepoetin (DEPO), methoxy polyethylene glycol-epoetin beta (CERA), hematide];
2. chorionic Gonadotrophin (CG) and luteinizing hormone (LH), prohibited in male sports only;
3. Insulins;
4. Corticotrophines;
5. Growth Hormone (GH), growth factor similar to insulin-1 (IGF-1), mechanical growth factors (MGF), growth factor derived from platelets (PDGF), fibroblastic growth factors (FGF), endothelial vascular growth factor (VEGF), hepatocyte growth factor (HGF) and any other growth factor influencing
6. Preparations derived from the platelets (e.g. "Platlet-rich plasma", "blood spinning") administered intramuscularly. Other routes of administration require a declaration of use in accordance with the international standard for the authorization of use for therapeutic purposes,
and other substances having a similar chemical structure or a similar biological effect(s).
S3. Beta-2 Agonists:
All beta-2 agonists (including both optical isomers if applicable) are prohibited, except salbutamol (maximum 1,600 micrograms per 24 hours) and salmeterol by inhalation, which require a declaration of use in accordance with the international standard for the authorization of use for therapeutic purposes.
The presence in the salbutamol urine at a concentration greater than 1000 ng/ml will be presumed not to be an intentional therapeutic use and will be considered an abnormal test result, unless the athlete proves by a controlled pharmacokinetic study that this abnormal result is indeed the consequence of the use of a therapeutic dose (maximum of 1,600 micrograms per 24 hours) of salbutamol by way
S4. Antagonists and hormonal modulators:
The following classes of substances are prohibited:
1. Aromatase inhibitors, including without limitation: aminoglutethhimide, anastrozole, androsta-1, 4, 6-triène-3,17-dione (androstatriènedione), 4-androstène-3,6,17 trione (6-oxo), exemestane, formstane, letrozole, testolactone.
2. Selective modulators of receptors to estrogen (SERM), including without limitation: raloxifen, tamoxifen, toremifen.
3. Other antiestrogogenic substances, including but not limited to: clomifene, cyclofenil, fulvestrant.
4. Modifying agents of myostatin function(s), including without limitation: myostatin inhibitors.
S5. Diuretics and other masking agents:
Agents are forbidden. They include:
Diuretics, probenecide, plasma substitutes (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl stardon and mannitol), and other substances with similar biological effect(s).
Diuretics include:
Acetazolamide, amiloride, bumetanide, canrenone, chlortalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamten and other substances with a similar chemical structure or
An authorization for use for therapeutic purposes for diuretics and masking agents is not valid if the urine sample of the athlete contains the (the) so-called substances(s) detected in combination with prohibited exogenous substances at their threshold levels or below their threshold levels.
METHODS
M1. Improvement of oxygen transfer:
The following is prohibited:
1. Blood doping, including the use of autologous blood products, counterparts or heterologists, or red blood cells of any origin.
2. Artificial improvement in the consumption, transport or release of oxygen, including without limiting perfluorinated chemicals, efaproxiral (RSR13) and modified hemoglobin products (e.g. blood substitutes based on hemoglobin, reticulated hemoglobin products) but excluding oxygen supplementation.
M2. Chemical and physical handling:
1. Falsification, or attempted falsification, with the aim of altering the integrity and validity of samples collected during doping controls, is prohibited. This category includes, without limitation, cathterization, substitution and/or alteration of urine (e.g. proteases).
2. Intravenous infusions are prohibited, except those legitimately received in hospital admissions or in clinical examinations.
M3. Genetic Doping:
The following, having the potential capacity to improve sports performance, is prohibited:
1. Transfer of cells or genetic elements (e.g. DNA, RNA).
2. The use of pharmacological or biological agents modulating gene expression.
The receptor agonists activated by the proliferators of the peroxysomes (PPAR) (e.g. GW 1516) and the agonists of the PPAR-protein kinase axis activated by the AMP (AMPK) (e.g. AICAR) are prohibited.
SUBSTANCES AND METHODS
IN COMPETITION
In addition to the categories S1 to S5 and M1 to M3 defined above, the following categories are prohibited in competition:
SUBSTANCES INTERDITES
S6. Stimulants:
All stimulants (including both optical isomers if applicable) are prohibited, with the exception of derivatives of imidazole for topical application and stimulants in the 2010 Surveillance Program (*).
Stimulants include:
(a) Stimulants not specified:
adrafinil, amphetamine, phepenamine, mephenamine
A stimulant that is not specifically named in this section is a specified substance.
(b) Specified stimulants (examples):
Adrenaline (**), cathine (***), ephedrine (****), etamivan, etiléfrine, fenbutrazate, fencamfamine, heptaminol, isomethen, levmethamfenamine, meclofenoxen, methylephedrine (****), methylphenidate, nicethamide, norfenefrine, octopamine
(*) Substances in the 2010 Surveillance Program (bupropion, caffeine, phenylpropanolamine, pipradrol, synephrine) are not considered prohibited substances.
(**) Adrenalin, associated with local anaesthetic agents, or in preparation for local use (e.g. nasal or ophthalmological), is not prohibited.
(***) Cathine is prohibited when its concentration in the urine exceeds 5 micrograms per millilitre.
(****) Ephedrine and methylephedrine are prohibited when their respective concentrations in the urine exceed 10 micrograms per millilitre.
(*****) The pseudoephedrine is prohibited when its concentration in the urine exceeds 150 micrograms per millilitre.
S7. Narcotics:
The following narcotics are prohibited:
Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocin, penthidine.
S8. Cannabinoids:
Natural or synthetic 9-tetrahydrocannabinol (THC) and THC analogues (e.g., haschisch, marijuana, HU-210) are prohibited.
S9. Glucocorticoids:
All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal.
In accordance with the international standard for the authorisation of therapeutic use, a declaration of use must be completed by the athlete for glucocorticoids administered by intra-articular, peri-articular, peri-tendent, peri-dural, intradermic and inhalation with the exception of the administrative routes listed below.
The topical preparations used to treat atrial, oral, dermatological (including iontophoresis/phonophorese), gingival, nasal, ophthalmological, and peri-analysis are not prohibited and therefore require no authorization for use for therapeutic purposes or declaration of use.
SUBSTANCES IN SPORTS
P1. Alcohol:
Alcohol (ethanol) is prohibited in competition only in the following sports. The detection will be performed by ethylometry and/or blood analysis. The violation threshold (hematological values) is 0.10 g/l;
Aeronautics (FAI);
Automobile (FIA);
Karate (WKF);
Motorcycling (FIM);
Motonautics (UIM);
Modern Pentathlon (UIPM) for the shot trials;
Quilles (Neuf - and Dix-) (FIQ) ;
Archery (FITA).
Betabloquants:
Unless otherwise stated, beta-blockers are prohibited in competition only in the following sports:
Aeronautics (FAI);
Automobile (FIA);
Billard and Snooker (WCBS);
Bobsleigh (FIBT);
Balls (CMSB);
Bridge (FMB);
Curling (WCF);
Gymnastics (FIG);
Golf (IGF) ;
(FILA)
Motorcycling (FIM);
Motonautics (UIM);
Modern Pentathlon (UIPM) for the shot trials;
Quilles (Neuf - and Dix-) (FIQ) ;
Ski (FIS) for ski jump, freestyle jump/halfpipe and snowboard halfpipe/big air ;
Shooting (ISSF, IPC) (also banned out of competition);
Archery (FITA) (also banned out of competition);
Sailing (ISAF) for racing game only;
Betabloquants include but are not limited to:
Acebutolol, alprenolol, aténolol, betaxolol, bisoprolol, bunolol, cartéolol, carvedilol, celiprolol, esmolol, labétalol, lévobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, proptalranolol, so
Done in Paris, February 10, 2010.
Nicolas Sarkozy
By the President of the Republic:
The Prime Minister,
François Fillon
Minister for Foreign Affairs
and European,
Bernard Kouchner
